젖소 유방염 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Bovine Mastitis Market, valued at USD 2 billion in 2024, is projected to grow at a CAGR of 6.3% from 2025 to 2034. This expansion is driven by several key factors, including the rising incidence of bovine mastitis, increasing awareness about animal health, and a growing demand for dairy products worldwide. As the dairy industry continues to scale up operations to meet the surging global demand, the need for effective disease management solutions has intensified.

Farmers and dairy producers are placing greater emphasis on improving cattle health and productivity, which is fueling investments in advanced diagnostic tools and innovative treatment solutions. Additionally, the heightened focus on sustainable dairy farming is prompting market players to explore non-antibiotic therapies, such as probiotics and vaccines, to address mastitis concerns while mitigating antimicrobial resistance. These industry-wide efforts are fostering a robust market landscape, making bovine mastitis treatment a critical area of growth in veterinary medicine.

The market is segmented into pharmaceuticals and diagnostics. The pharmaceutical segment includes antibiotics, vaccines, and other treatment solutions aimed at combating infections in dairy cattle. Antibiotics such as penicillin and cephalosporin remain widely used for mastitis treatment, while ongoing innovations in intramammary infusion therapies are enhancing treatment efficacy. With dairy producers seeking fast and effective solutions, pharmaceutical companies are focusing on improving drug formulations to reduce antibiotic resistance and improve recovery rates in affected cattle. Meanwhile, the diagnostics segment is experiencing steady growth due to the increasing adoption of early detection methods, allowing for timely intervention and better herd management.

The bovine mastitis market is further categorized by type into clinical and subclinical mastitis. In 2024, clinical mastitis accounted for 55% of the market, primarily due to its visible symptoms and the significant impact on milk production. The immediate economic losses associated with clinical mastitis make it a top priority for dairy farmers and veterinarians. Growing awareness about the condition, along with a wider range of available treatment options, is supporting market growth. At the same time, concerns over antimicrobial resistance are pushing the industry towards alternative treatment approaches. Non-antibiotic therapies, including probiotics, vaccines, and herbal formulations, are gaining traction as sustainable solutions that align with regulatory shifts and consumer demand for antibiotic-free dairy products.

The U.S. Bovine Mastitis Industry was valued at USD 683 million in 2024, reflecting consistent growth over recent years. The country's large livestock population, coupled with increasing demand for high-quality milk, is driving expansion in dairy farming and veterinary services. With a strong emphasis on cattle health, dairy farmers are adopting more sophisticated treatment solutions and precision livestock farming technologies. This trend is expected to further accelerate advancements in bovine mastitis management, reinforcing the U.S. market's leadership in veterinary innovation and dairy productivity.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global dairy consumption
    • 3.2.1.2 Advancements in mastitis detection technologies
    • 3.2.1.3 Growing awareness of animal health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Antibiotic resistance concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmaceutical
  • 5.2.1 Antibiotics
  • 5.2.2 Vaccines
  • 5.2.3 Other pharmaceuticals
• 5.3 Diagnostics

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical mastitis
• 6.3 Sub-clinical mastitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Intra-mammary
• 7.3 Systemic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Diagnostic laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Advanced Animal Diagnostics
• 10.2 Boehringer Ingelheim
• 10.3 Ceva
• 10.4 DeLaval
• 10.5 Elanco
• 10.6 Heilsaa
• 10.7 HIPPRA
• 10.8 ImmuCell Corporation
• 10.9 Merck & Co
• 10.10 Norbrook
• 10.11 Virbac
• 10.12 Zoetis